Friday, 20 Apr 2018

You are here

Supreme Court Decision Favors Earlier Biosimilar Adoption

On Monday June 11th, the US Supreme Court unanimously ruled that biosimilar manufacturers can bring their drugs to market faster by eliminating the provision that the biosimar manufacturer had to give the innovator company 180 days notice before launching the new biosimilar.

The court was asked to decide on biosimilar patent dispute resolution procedures of the Biologics Price Competition and Innovation Act (BPCIA) or what has been called the "patent dance".  In the first part of the patent dance, the Court ruled against the requirement that a biosimilar applicant share its biosimilar application with the reference product sponsor.

The second ruling regarding a premarketing notice requirement, the Court held that the biosimilar applicant does not have to wait for FDA approval before giving 180-day premarketing notice, as long as there are no existing injunctions stemming from pending patent litigation.

The judgement stems from a dispute in Sandoz v. Amgen over Zarxio (the first biosimilar approved) competing with Amgen's Neulasta (pegfilgastrim or G-CSF).  A lower court had previously ruled against Sandoz challenge to the 180 day wait.  The Supreme Court ruled 9-0 in favor of Sandoz's assertion that a biosimilar manufacturers should not have to wait an extra six months after FDA approval to launch the new biosimilar product.

Sandoz's drug costs about 15 percent less than the brand name and Amgen has had 12 years of market exclusivity with the product. Sandoz argued that the 180 day could cost them millions in sales.

The 6 month wait orginated in a provision of the Affordable Care Act that requires a biosimilar manufacturer to give the brand-name manufacturer 180 days notice before launching.

While this a setback for Amgen, the FDA just rejected Coherus' biosimilar Neulasta (pegfilgastrim) where the FDA's complete response letter cited the need for more information regarding immunogenicity and manufacturing. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

IL-6 Inhibition Most Effective in Polycyclic Systemic JIA

The German Autoinflammatory Disease (AID) registry has studied the effects of the IL-6 inhibitor tocilizumab (TCZ) in systemic juvenile idiopathic arthritis (sJIA) patients and shown a clinical response rate of 35% during the first 12 weeks, and inactive disease and/or remission (with medication) in 75% at 12 months.

Rituximab May Halt ILD in Antisynthetase Syndrome Myositis

A multicenter study assessed patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) and found that rituximab (RTX) therapy was associated with either improved or stable pulmonary outcomes in most. 

Anakinra May Attenuate Stroke Outcomes

The journal Stroke has published a trial wherein the use of subcutaneous IL-1Ra (anakinra) was shown to reduce the peripheral inflammatory response in those with an acute ischemic stroke. (Citation source: http://bit.ly/2uoNXEL)

FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis

Yesterday a FDA advisory panel voted 15-0 in favor of approving Xeljanz (tofacitinib) 10 mg bid for patients with moderate to severe ulcerative colitis.

The US Food and Drug Administration’s (FDA) convened the Gastrointestinal Drugs Advisory Committee Meeting (GIDAC) to assess Pfizers supplemental new drug application for tofacitinib in adult patients with moderately to severely active ulcerative colitis (UC).

Abatacept Efficacy in JIA

Subcutaneous abatacept (Orencia) showed efficacy among children with polyarticular juvenile idiopathic arthritis (JIA) in an open-label phase III trial.